Advertisement

Topics

Canada OKs Gillad's Biktarvy For Treatment Of HIV-1 Infection

05:45 EDT 13 Jul 2018 | Pharmaceutical Processing

The approval of Biktarvy is supported by data from four ongoing Phase 3 studies, including in treatment-naïve HIV-1 infected adults and virologically suppressed adults.
Contributed Author: 
Gilead Sciences, Inc.

Original Article: Canada OKs Gillad's Biktarvy For Treatment Of HIV-1 Infection

NEXT ARTICLE

More From BioPortfolio on "Canada OKs Gillad's Biktarvy For Treatment Of HIV-1 Infection"

Advertisement
Quick Search
Advertisement
Advertisement